Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vagus nerve stimulation in depression.

P J Goodnick1, A J Rush, M S George

  • 1University of Miami School of Medicine, FL 33136, USA. pgoodnick@aol.com

Expert Opinion on Pharmacotherapy
|October 5, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Resolutions of Delta County Medical Society.

Daniel's Texas medical journal·2023
Same author

The 'difficult-to-treat depression' and the 'response paradigm' models: Implications and relevance to patient management.

The Australian and New Zealand journal of psychiatry·2021
Same author

The identification, assessment and management of difficult-to-treat depression: An international consensus statement.

Journal of affective disorders·2020
Same author

Treatment modalities and outcomes of pleomorphic hyalinizing angiectatic tumor: a systematic review of the literature.

Musculoskeletal surgery·2018
Same author

Increased hippocampal tail volume predicts depression status and remission to anti-depressant medications in major depression.

Molecular psychiatry·2017
Same author

Epidemiology of mental health comorbidity in psoriasis.

The Journal of dermatological treatment·2017
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Vagus nerve stimulation (VNS) shows promise for treating resistant depression, with positive outcomes and no cognitive impairment. This biological therapy is approved in Europe and Canada, with US trials ongoing.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Medical Devices

Background:

  • Biological treatments for psychiatric disorders have evolved significantly since the mid-20th century.
  • Vagus nerve stimulation (VNS) was initially approved for drug-resistant epilepsy.
  • VNS demonstrated potential for mood disorders due to its neuroanatomical pathways and effects on neurotransmitters.

Purpose of the Study:

  • To investigate the efficacy and safety of VNS for treatment-resistant depression.
  • To evaluate both acute and longer-term outcomes in patients with mood disorders receiving VNS.

Main Methods:

  • Acutely administered VNS for 10 weeks in 60 patients with treatment-resistant depression.
  • Longer-term follow-up data analyzed for 30 patients.
  • Comparison of outcomes with epilepsy treatment and long-term medication trials.

Related Experiment Videos

Main Results:

  • Acute VNS study showed response rates of at least 30%.
  • Longer-term data indicated promising symptomatic and functional outcomes.
  • VNS was not associated with cognitive impairment, unlike electroconvulsive therapy.

Conclusions:

  • VNS is a viable treatment option for resistant depression (unipolar or bipolar).
  • VNS has received regulatory approval in Europe and Canada.
  • Ongoing US studies aim to further validate VNS efficacy in depression treatment.